Michael Y. Choi

机构：University of San Diego, University of California, San Francisco, Sanford Burnham Prebys Medical Discovery Institute, UC San Diego Health System, University of California San Diego, NovelMed Therapeutics (United States), University of California San Diego Medical Center, Moores Cancer Center · ORCID：0000-0002-9107-2186

发表论文 185 篇 · 总被引 4907 次 · h-index 38

代表论文

• Mutation in Bruton Tyrosine Kinase (BTK) A428D confers resistance To BTK-degrader therapy in chronic lymphocytic leukemia (2024 · Leukemia · 被引 32)
• Conserved long noncoding RNA TILAM promotes liver fibrosis through interaction with PML in HSCs (2024 · Hepatology · 被引 8)
• A Phase 2 Study of MORF-057, an Oral α4β7 Integrin Inhibitor in Moderately to Severely Active Ulcerative Colitis (2025 · Clinical Gastroenterology and Hepatology · 被引 3)
• Aberrant spliceosome activity via elevated intron retention and upregulation and phosphorylation of SF3B1 in chronic lymphocytic leukemia (2024 · Molecular Therapy — Nucleic Acids · 被引 3)
• Clinical strategies for lymphoma management: Recommendations from the Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Consensus Conference 2025 (2026 · Cancer · 被引 1)
• A novel application of deep learning (DL)-based MRI with liquid biomarkers for immune effector cell-associated neurotoxicity syndrome (ICANS) after chimeric antigen receptor (CAR) T-cell therapy. (2025 · Journal of Clinical Oncology · 被引 1)